Discovery of a novel VEGFR2 inhibitor using integrated structure-based docking study and functional validation:...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer is a leading cause of death globally, with current treatments facing challenges like drug resistance and side effects.
• Vascular endothelial growth factor receptor 2 (VEGFR2) is crucial for tumor angiogenesis, making it a promising therapeutic target.
• Developing novel inhibitors for VEGFR2 is essential for advancing anti-angiogenic cancer therapies.

Purpose of the Study:

• To identify novel inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2) using an integrated computational and experimental approach.
• To evaluate the anti-proliferative and kinase inhibitory activities of potential VEGFR2 inhibitors.
• To discover a lead compound for the development of new anti-angiogenic and anticancer agents.

Main Methods:

• Screened a library of over 2,000 compounds using structure-based molecular docking against the VEGFR2 crystal structure.
• Performed detailed binding interaction analyses and redocking simulations to explore ligand binding modes.
• Conducted cytotoxicity assays on VEGFR2-overexpressing U87 cells and enzymatic assays to confirm VEGFR2 kinase inhibition.

Main Results:

• Identified several high-ranking compounds with significant anti-proliferative effects in VEGFR2-overexpressing U87 cells.
• Confirmed the potent VEGFR2 kinase inhibitory activity of one novel compound.
• Detailed binding interactions revealed the mechanism of inhibition for the lead compound.

Conclusions:

• A novel compound has been identified as a potent inhibitor of VEGFR2.
• This lead compound demonstrates potential as an anti-angiogenic and anticancer therapeutic agent.
• Further optimization of this compound is warranted for clinical development.